Replidyne has cut about a third of its workforce and dumped one of its development programs in a restructuring. The company announced that most of the cuts were in administration, clinical, regulatory, and commercial operations while it was suspending work on a topical antibiotic, REP8839. A late-stage trial for faropenem in acute exacerbation of chronic bronchitis is continuing. Replidyne was a 2006 Fierce 15 company.
- check out this release
- here's the AFX report on the restructuring